Recently, inhibition of PPARγ Ser245 phosphorylation by noncanonical agonist PPARγ ligands has been shown to deregulate tumor-suppressor p53 signaling, sensitizing cancer cells to cytotoxic chemotherapy [46]. The gene discussed is PPARG; the disease is neoplasm.